EyePoint, Inc. (EYPT) Stock
EYPT has an Alpha Score of 11 out of 100 (poor), computed on Nov 4, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported EYPT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $28.28M. Company insiders reported 1 open-market buy and 0 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is EYPT's Alpha Score?
How it works →Alpha Score of 11 reflects poor overall profile with poor momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own EYPT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.98M | $28.28M | +4% |
| Millennium Management Israel Englander | 500K | $7.15M | +5% |
| Point72 Steve Cohen | 49K | $694.6K | NEW |
| Marshall Wace | 24K | $342.3K | -85% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are EyePoint, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 18, 26 | Zaderej Karen L. | Director | BUY | 10.6K | $52K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are EYPT's key statistics?
Key statistics as of Nov 11, 2026
EYPT price chart
Powered by TradingViewWhat does EyePoint, Inc. do?
EyePoint Pharmaceuticals Inc. is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products. Its primary purpose is to treat serious eye disorders, particularly targeting diseases like wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion. EyePoint's unique approach leverages drug delivery technologies which offer sustained-release treatments, enhancing patient outcomes by providing consistent therapeutic levels over extended periods. The company operates within the biotechnology and healthcare sectors, impacting the pharmaceutical landscape by addressing unmet medical needs in ophthalmology. EyePoint Pharmaceuticals plays a significant role in the market through collaborations with leading eye care companies, advancing therapeutic research and expanding access to novel solutions for visual impairment. Based in Watertown, Massachusetts, the company continues to innovate and lead in the field of ocular drug development, contributing to the advancement of vision-related healthcare on a global scale.